Table 1.
Demographic | mDOT | SAT |
---|---|---|
Number of subjects | 12 | 9 |
Mean age (range) in years | 40 (29–51) | 43 (36–54) |
Gender | ||
Female | 7 | 3 |
Male | 5 | 6 |
Race/ethnicity | ||
African-American | 1 | 1 |
Hispanic | 0 | 3 |
Caucasian | 11 | 5 |
Mean (range) years of nonconsecutive opioid use | 8 (1–25) | 15 (3–37) |
Mean (range) duration of current methadone maintenance (months) | 140 (1–36) | 149 (7–29) |
Genotype | ||
1, 4 | 8 | 6 |
2, 3 | 4 | 3 |
Biopsy staging (only GT 1,4) | ||
2 | 4 | 4 |
3 | 2 | 0 |
4 | 2 | 2 |
HIV coinfection | 3 | 3 |
Depressive disorders | 8 | 5 |
Anxiety disorders | 8 | 3 |
Diagnostic and Statistical Manual of Mental Disorders-IV criteria for alcohol abuse/dependence | 4 | 2 |
Diagnostic and Statistical Manual of Mental Disorders-IV criteria for cocaine abuse/dependence | 9 | 7 |
Positive cocaine urine toxicology in 30 days prior to study enrollment | 3 | 4 |
Note: HCV, hepatitis C virus; GT, genotype; mDOT, modified directly observed therapy; SAT, self-administered therapy.